Kemwell to double European capacity

India-based contract manufacturer Kemwell is nearly doubling its space at a facility in Uppsala, Sweden. Construction is on a fast track: The company says production in the new facility will begin this year.

The building is a 16,000-square-meter former Pfizer plant, from which Kemwell launched its European business four years ago. The CMO is boosting its operations space to 31,000 square meters to keep pace with growth.

It will use the additional space to increase production of the tablets, suppositories and capsules that are its mainstays, as well as readying the manufacturer to expand into other product types. New formulations also are in the plans, as is expansion of contractor's analytical and method development service offerings and stability studies.

- see this article

Suggested Articles

AbbVie will soon own Allergan’s prized Botox franchise, and along with its roughly $4 billion in sales, it will get a new $176 million plant.

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

The FDA has found some issues with Biocon’s small molecule plant in Bengaluru, India.